RPTX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

--

Open

--

VWAP

--

Vol

--

Mkt Cap

143.47M

Low

--

Amount

--

EV/EBITDA(TTM)

--

Total Shares

--

EV

1.63M

EV/OCF(TTM)

--

P/S(TTM)

9.55

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

Show More

Events Timeline

(ET)

2026-01-16

17:10:00

Repare Therapeutics Shareholders Approve Acquisition

2025-12-24 (ET)

2025-12-24

07:20:00

Repare Therapeutics Enters $30 Million Asset Purchase Agreement with Gilead Sciences

2025-11-14 (ET)

2025-11-14

16:58:48

Repare Therapeutics announces Q3 earnings per share of 8 cents compared to a loss of 81 cents in the previous year.

2025-11-14

16:50:01

XenoTherapeutics to Purchase Repare Therapeutics for $1.82 per Share Along with One Contingent Value Right

2025-08-08 (ET)

2025-08-08

07:35:48

Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year

2025-07-15 (ET)

2025-07-15

16:06:28

Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib

2025-05-13 (ET)

2025-05-13

16:07:50

Repare Therapeutics expects cash to fund operations through 2027

News

NASDAQ.COM

2025-12-26NASDAQ.COM

Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway

NASDAQ.COM

2025-12-24NASDAQ.COM

Repare Therapeutics Surges 18.9% Leading Biotechnology Sector Gains

NASDAQ.COM

2025-12-24NASDAQ.COM

Repare Therapeutics Acquires Gilead's RP-3467 for Up to $30 Million

Benzinga

2025-12-24Benzinga

Gilead Acquires Repare Therapeutics' RP-3467 for Up to $30 Million

PRnewswire

2025-12-18PRnewswire

Halper Sadeh Investigates United Security Bancshares Acquisition by Community West

Globenewswire

2025-12-08Globenewswire

Confluent, Inc. to be Sold to IBM for $31.00 per Share Amid Legal Investigation

2 Analyst Rating

Wall Street analysts forecast RPTX stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

Current: 0.000

Low

3.00

Averages

3.00

High

3.00

TD Cowen

Marc Frahm

Buy

to

Hold

downgrade

$1.82

AI Analysis

2025-11-17

Reason

TD Cowen

Marc Frahm

Price Target

$1.82

AI Analysis

2025-11-17

downgrade

Buy

to

Hold

Reason

TD Cowen analyst Marc Frahm downgraded Repare Therapeutics to Hold from Buy after the company agreed to be acquired by XenoTherapeutics for an estimated $1.82 per share. TD sees little risk to the deal closing.

H.C. Wainwright

Buy

downgrade

$5 -> $3

2025-10-27

Reason

H.C. Wainwright

Price Target

$5 -> $3

2025-10-27

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Repare Therapeutics to $3 from $5 and keeps a Buy rating on the shares. The firm says the initial RP-1664 data "raises questions over its viability." As such, the firm removed risk-adjusted revenue forecasts for the agent.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RPTX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Repare Therapeutics Inc (RPTX.O) is -2.69, compared to its 5-year average forward P/E of -4.98. For a more detailed relative valuation and DCF analysis to assess Repare Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.98

Current PE

-2.69

Overvalued PE

0.52

Undervalued PE

-10.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.40

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.33

Undervalued EV/EBITDA

-6.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

53.15

Current PS

11.08

Overvalued PS

160.13

Undervalued PS

-53.83

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

give me penny stocks to invest in

Intellectia · 7 candidates

Market Cap: <= 1000.00MPrice: <= $5.00Net Margin: >= 5.00Weekly Average Turnover: >= 1,000,000Quarter Revenue Qoq Growth: >= 20.0%

Ticker

Name

Market Cap$

Kopin Corp

529.00M

Organogenesis Holdings Inc

487.34M

Bridger Aerospace Group Holdings Inc

155.52M

Upexi Inc

132.74M

BTCS Inc

126.36M

Repare Therapeutics Inc

111.65M

give me 5 more that are bullish

Intellectia · 23 candidates

Price: <= $3.00Weekly Average Turnover: >= 1,000,000Rsi 14: <= 70Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Quarter Eps Qoq Growth: >= 10.0%Quarter Revenue Qoq Growth: >= 10.0%

Ticker

Name

Market Cap$

Companhia Siderurgica Nacional SA

2.36B

Prospect Capital Corp

1.33B

Iovance Biotherapeutics Inc

996.39M

loanDepot Inc

893.07M

Ecarx Holdings Inc.

734.56M

Bit Digital Inc

721.79M

Best penny stocks to buy right now

Intellectia · 10 candidates

Market Cap: <= 2.00BPrice: <= $5.00Net Margin: >= 5.00Weekly Average Turnover: >= 1,000,000Quarter Eps Qoq Growth: >= 10.0%Quarter Revenue Qoq Growth: >= 15.0%

Ticker

Name

Market Cap$

Prospect Capital Corp

1.33B

Bit Digital Inc

721.79M

Kopin Corp

529.00M

Organogenesis Holdings Inc

487.34M

Bridger Aerospace Group Holdings Inc

155.52M

Upexi Inc

132.74M

Whales Holding RPTX

BVF Partners L.P.

Redmile Group, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Repare Therapeutics Inc (RPTX) stock price today?

The current price of RPTX is 0 USD — it has increased 0

What is Repare Therapeutics Inc (RPTX)'s business?

Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.

What is the price predicton of RPTX Stock?

Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Repare Therapeutics Inc (RPTX)'s revenue for the last quarter?

Repare Therapeutics Inc revenue for the last quarter amounts to 11.62M USD, decreased

What is Repare Therapeutics Inc (RPTX)'s earnings per share (EPS) for the last quarter?

Repare Therapeutics Inc. EPS for the last quarter amounts to 0.08 USD, decreased -109.88

How many employees does Repare Therapeutics Inc (RPTX). have?

Repare Therapeutics Inc (RPTX) has 129 emplpoyees as of March 12 2026.

What is Repare Therapeutics Inc (RPTX) market cap?

Today RPTX has the market capitalization of 143.47M USD.